Glofitamab-gxbm bulk supplier for pharma manufacturers

Glofitamab-Gxbm 1 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 1 mg/mL

Reference Brands: Columvi (USA/EU)

Glofitamab-gxbm is a bispecific monoclonal antibody that targets both CD20 (on B cells) and CD3 (on T cells). It helps the patient’s immune system attack and destroy malignant B cells. It is indicated for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Glofitamab-Gxbm — third party manufacturing & bulk supply

Glofitamab-Gxbm 1 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Glofitamab-Gxbm is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Glofitamab-Gxbm listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Glofitamab-Gxbm →

Back to Listing

Frequently Asked Questions

Glofitamab-gxbm is listed as Injection in 1 mg/mL. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Glofitamab-gxbm is referenced against Columvi (USA/EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.